Recent Pfizer Press Releases

  • 11/15/16 8:00 am EST

    Detailed Results from Two Phase 3 Studies Featured in Oral & Poster Presentations at 2016 ACR/ARHP Annual Meeting

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that new results from the Phase 3 Oral Psoriatic Arthritis TriaL (OPAL) studies, Broaden and Beyond, will be presented at the 2016 ACR/ARHP Annual Meeting (November 11-16, Washington, DC). OPAL Broaden and OPAL Beyond evaluated the efficacy and safety of XELJANZ® (tofacitinib citrate) in adult patients with active psoriatic arthritis (PsA) who had an inadequate response (IR) to conventional syntheticmore...
  • 11/14/16 8:00 am EST

    Cooperative Research and Development Agreement (CRADA) assesses OX40 agonist, utomilumab and avelumab immuno-oncology assets alone and in various combinations

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). As part of the CRADA, Pfizer will collaborate with NCI’s Center for Cancer Research (CCR) to arrange and conduct preclinical and clinical trials to evaluate three investigational immunotherapy agents. These include Pfizer’s proprietarymore...
  • 11/11/16 6:00 am EST

    Prevenar 13® Vaccine Will Be Available at Lowest Price for Humanitarian Emergencies

    Pfizer to Donate Sales Proceeds to Organizations Supporting the Refugee Crisis

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today a major expansion of its humanitarian assistance program enabling broader access to its vaccine, Prevenar 13, in humanitarian emergency settings by offering its new multi-dose vial (MDV) at what will be the lowest prevailing global price, currently $3.10 per dose. In addition, given the acute need for aid on the ground, Pfizer will donate all sales proceeds for the first year of this program to humanitarianmore...
  • 11/7/16 6:45 am EST

    Results of Phase 3 Studies for Investigational XELJANZ for Psoriatic Arthritis to be Presented at 2016 ACR/ARHP Annual Meeting

    Twenty Presentations at 2016 ACR/ARHP Annual Meeting Reinforce Pfizer’s Leadership in Inflammation and Immunology

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that 20 abstracts for XELJANZ® (tofacitinib citrate) will be presented at the upcoming 2016 ACR/ARHP Annual Meeting (November 11-16, Washington, DC). Notably, results from the two pivotal Phase 3 OPAL (Oral Psoriatic Arthritis TriaL) studies of tofacitinib – the only Janus kinase (JAK) inhibitor under investigation for psoriatic arthritis (PsA) – will be presented for the first time. OPAL Broaden will bemore...
  • 11/1/16 6:30 am EDT

    Company will record a charge to GAAP and Adjusted earnings in the fourth quarter of 2016 estimated to be approximately $0.04 per share

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of the global clinical development program for bococizumab, its investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i). The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates that bococizumab is not likely to provide value to patients, physicians, ormore...
  • 10/19/16 6:02 pm EDT

    Recommendation provides updated guidance for administering a two- or a three-dose series

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend that: For persons at increased risk for meningococcal disease and for use during serogroup B outbreaks, 3 doses of TRUMENBA should be administered at 0, 1-2, and 6 months When given to healthy adolescents who are not at increased riskmore...
  • 10/9/16 10:30 am EDT

    Data From a Trial of INLYTA With Pembrolizumab Provides Additional Support for Novel Immunotherapy Combinations in RCC

    Preliminary Results from an Ongoing Trial of INLYTA with Avelumab in RCC Were Also Presented

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced data from an ongoing, investigational Phase 1b study of INLYTA® (axitinib) combined with the checkpoint inhibitor pembrolizumab (A4061079, NCT02133742), a PD-1 inhibitor known as KEYTRUDA® and marketed by Merck, known as MSD outside the United States and Canada, in treatment-naïve patients with advanced renal cell carcinoma (RCC). The study was designed to establish dosing and evaluate the safety and anti-more...
  • 9/28/16 6:00 am EDT

    20 abstracts across multiple tumor types; unique mechanisms of action address the diverse needs of people living with cancer

    New combination study data in renal cell carcinoma and first-in-human results for OX40 agonist provide new insights in immuno-oncology

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it will be presenting data from 20 abstracts, including three late-breakers, at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen from October 7-11, 2016. The presentations demonstrate progress addressing cancer’s complex challenges through our work across 11 tumor types and eight distinct mechanisms of action, including two immuno-oncology/targeted therapy combinationmore...
  • 9/23/16 8:30 am EDT
    • Transaction expected to close in the Third-Quarter 2016
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended has expired with respect to Pfizer’s pending acquisition of Medivation, Inc. (NASDAQ: MDVN). Pfizer now expects to complete the acquisition in the Third-Quarter 2016. The closing of the tender offer remains subject to other customary closing conditions, including the tender of a majority of themore...
  • 9/14/16 6:14 pm EDT
    NEW YORK--(BUSINESS WIRE)--Today, a joint meeting of the U.S. Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee reviewed data from EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study) evaluating the neuropsychiatric safety of CHANTIX® (varenicline). The Committees recommended by a majority vote to remove the boxed warning regarding serious neuropsychiatric adverse eventsmore...